Urologic Oncology-Seminars and Original Investigations

Papers
(The TQCC of Urologic Oncology-Seminars and Original Investigations is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Festschrift essay to celebrate Dr. Michael Droller110
Cover 2 - Masthead59
Genetic variations related to the prostate cancer risk: A field synopsis and revaluation by Bayesian approaches of genome-wide association studies49
GROWTH OF VON HIPPEL-LINDAU (VHL)-ASSOCIATED RENAL TUMORS DURING PREGNANCY47
A QUALITATIVE EXPLORATION OF THE EXPERIENCE OF TRANSGENDER AND GENDER NONCONFORMING PATIENTS WITH GENITOURINARY AND GYNECOLOGIC MALIGNANCIES31
UTILITY OF C-REACTIVE PROTEIN LEVELS IN IMPROVING RISK STRATIFICATION IN METASTATIC RENAL CELL CARCINOMA31
Investigation of prognostic biomarkers in patients with urothelial carcinoma treated with platinum-based regimens30
Predictors of discharge to home following major surgery for urologic malignancies: Results from the national surgical quality improvement program29
REAL-WORLD ANALYSES OF MACE AND MORTALITY RISK IN PATIENTS WITH PROSTATE CANCER AFTER INITIATION OF LHRH AGONISTS VS. GNRH ANTAGONIST28
PREVALENCE OF OCCULT UROLOGIC MALIGNANCIES IN PATIENTS UNDERGOING SCREENING FOR LUNG CANCER28
DECIPHER® GENOMIC CLASSIFIER SCORE ON INITIAL BIOPSY IS ASSOCIATED WITH PROGRESSION FORM ACTIVE SURVEILLANCE TO TREATMENT IN PROSTATE CANCER28
PREOPERATIVE RADICAL CYSTECTOMY ERAS SCREENING AND EDUCATION – PATIENT REPORTED OUTCOMES28
APPLICATION OF THE STRATCANS CRITERIA TO THE MUSIC AS COHORT: A STEP TOWARDS RISK STRATIFIED ACTIVE SURVEILLANCE28
“Published abstracts from the 24th Annual Meeting of the Society of Urologic Oncology”27
Predictive factors associated with differential pathologic response to neoadjuvant chemohormonal therapy in high-risk localized prostate cancer27
The role of enhanced recovery after surgery protocols in the development of acute kidney injury following radical cystectomy27
Guideline discordant care in patients with metastatic germ cell tumors26
Cover 2 - Masthead25
Editorial Board24
Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study24
Exploring prostate-specific antigen (PSA) Testing rates and screening disparities in the all of us dataset23
Safety and efficacy of intravesical Bacillus Calmette-Guerin instillation for superficial recurrence following bladder-sparing therapy of muscle invasive bladder cancer: A retrospective study23
Extracellular vesicles in renal cell carcinoma: A review of the current landscape and future directions22
NON-MUSCLE INVASIVE RECURRENCE AND MANAGEMENT DURING SURVEILLANCE IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO ACHIEVE CLINICAL COMPLETE RESPONSE TO NEOADJUVANT CHEMOTHERAPY22
Radical prostatectomy readmissions: Causes, risk factors, national rates, & costs22
Postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) for seminoma: Limitations of surgical intervention after first-line chemotherapy21
Clinical impact of detrusor muscle in en bloc resection for T1 bladder cancer21
Radical prostatectomy for patients with high-risk, very-high risk, or radiographic suspicion for metastatic prostate cancer: Perioperative and early oncologic results from the MUSIC statewide collabor20
Review of radiopharmaceutical therapy in prostate cancer19
Cover 3 - GF 39719
Cut-offs for relapse detection in men with stage I testicular germ cell tumors during active surveillance within a prospective multicentre cohort study using either raw or housekeeper normalized miR-319
Re: Beyond tunnel vision—Reconsidering real-world evidence on staging in intermediate-risk prostate cancer19
COMUTATIONAL PATTERNS IN FGFR3-ALTERED NON-MUSCLE INVASIVE BLADDER CANCER INFLUENCE RECURRENCE AND PROGRESSION19
Low co-expression of PD-L1 and oncogenic receptor tyrosine kinases HER2 and cMET in urothelial carcinoma is associated with discordant expression between primary and metastatic sites19
Multicenter study of active surveillance for small renal masses: Real world practice pattern18
Impact of the controlling nutritional status (CONUT) score on perioperative morbidity and oncological outcomes in patients with bladder cancer treated with radical cystectomy18
The identification of clinicopathological features predictive of recurrence following lymphadenectomy in penile cancer: A systematic review18
Morbidity and mortality of multivisceral resection with radical nephrectomy for locally advanced renal cell carcinoma: An analysis of the National Surgical Quality Improvement Program (NSQIP) database18
Comment on “optimizing radical cystectomy recovery: The role of modified ERAS in improving postoperative outcomes”17
PSA response to predict progression in metastatic hormone-sensitive prostate cancer (mHSPC) patients. When is the optimal time point?17
Beyond PSA90: Deep PSA response predicts outcomes in nonmetastatic CRPC17
Managing female sexual dysfunction17
PSA kinetics and predictors of PSA response in metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors17
Guidelines versus real-world data in metastatic bladder cancer: A population-based study on first-line chemotherapy treatment patterns17
Ideal candidates for bladder preservation in muscle-invasive bladder cancer17
Salvage local treatment for recurrent prostate cancer after focal therapy: A systematic review and meta-analysis16
AUTOMATED NEPHROMETRY SCORES THROUGH DIRECT PREDICTION OF EACH COMPONENT16
CLINICAL PROGRESSION OF PROSTATE CANCER FROM ACTIVE SURVEILLANCE IS PREDICTED BY DECIPHER® GENOMIC CLASSIFIER SCORE ON INDEX BIOPSY INDEPENDENT FROM RISK ASSESSMENT BY MRI CHARACTERISTICS16
TUMOROID AND GENOMIC MODELING OF LOW GRADE INTERMEDIATE RISK BLADDER CANCER TO PREDICT INTRAVESICAL CHEMOTHERAPY RESPONSE16
IMMEDIATE LYMPHATIC RECONSTRUCTION WITH LYMPHATICOVENOUS BYPASS CREATION AFTER BILATERAL INGUINAL LYMPH NODE DISSECTION FOR PENILE CANCER: A CASE SERIES16
Novel immunotherapies for prostate cancer16
Lack of survival benefit of pelvic lymph node dissection for patients with radical prostatectomy and postprostatectomy radiotherapy16
Efficacy and safety of tislelizumab plus intravesical chemotherapy in recurrent high-risk non-muscle-invasive bladder cancer: A retrospective single-center real-world study16
Sterotactic ablative radiotherapy vs. thermal ablation of localized renal cell carcinoma: Is there a preferred second-line management option?16
Conditional survival of stage III non-seminoma testis cancer patients15
Immune mechanisms and molecular therapeutic strategies to enhance immunotherapy in non–muscle invasive bladder cancer15
Laboratory paraneoplastic syndrome resolution is associated with reduced recurrence and improved survival in non-metastatic renal cell carcinoma15
Comparison of microwave ablation and partial nephrectomy for T1a small renal masses15
Recurrence patterns in primary urethral carcinoma: Prognostic impact of inguinal and pelvic lymphadenectomy15
A comparison of outcomes between transperitoneal and retroperitoneal robotic assisted partial nephrectomy in patients with completely endophytic kidney tumors15
Prospective validation of clino-radio-pathological risk scoring system (CRiSS) for prediction of inguinal lymph-nodes metastasis in squamous cell carcinoma of penis15
Cover 2 - Masthead15
Diagnostic performance of 68Ga-PSMA-11 PET/MRI in biochemical recurrent prostate cancer after radical prostatectomy and prediction nomogram15
PSYCHOLOGICAL RESILIENCE AND DISTRESS AMONG RADICAL CYSTECTOMY PATIENTS: A SYMPTOM DISTRESS SCALE SURVEY ANALYSIS14
UTILIZING LOW-PASS WHOLE GENOME SEQUENCING OF URINARY-TUMOR DNA TO IDENTIFY MINIMAL RESIDUAL DISEASE PRIOR TO REPEAT TRANSURETHRAL RESECTION OF BLADDER TUMOR14
DEFINING THE IMPACT OF PERSONAL AND FAMILY HISTORY OF LYNCH-SYNDROME ASSOCIATED CANCERS ON CLINICAL CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA14
INTENSIFIED MRI-BASED PROSTATE CANCER SCREENING IN GERMLINE CARRIERS OF RARE PATHOGENIC VARIANTS: INTERIM RESULTS FROM THE INITIAL SCREENING ROUND OF THE PROGRESS STUDY14
Survival trends in chemotherapy exposed metastatic bladder cancer patients and chemotherapy effect across different age, sex, and race/ethnicity14
IMPACT OF NODAL DISEASE IN NON-CLEAR CELL RENAL CELL CARCINOMA AND THE ROLE OF SALVAGE LYMPH NODE RESECTION14
COMPARING WHITE LIGHT VERSUS BLUE LIGHT CYSTOSCOPY RECURRENCE OUTCOMES AMONG NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS IN AN EQUAL ACCESS SETTING: A PROPENSITY SCORED MATCHED ANALYSIS14
Tumors masquerading as type 2 papillary renal cell carcinoma: pathologists’ ever-expanding differential diagnosis for a heterogeneous group of entities14
FEASIBILITY AND OUTCOMES OF INTERVENTIONS TO REDUCE CYSTOSCOPY DISCOMFORT: A QUALITY IMPROVEMENT PILOT14
CHEST CT SHOULD REPLACE CHEST X-RAYS TO EVALUATE FOR THORACIC RENAL CELL CARCINOMA METASTASES14
Multivariate analysis of the parameters affecting the choice of surgical treatment for patients with localized renal cell carcinoma (RCC)13
Impact of modified Glasgow prognostic score on predicting prognosis and modification of risk model for patients with metastatic renal cell carcinoma treated with first line tyrosine kinase inhibitor13
FACTORS ASSOCIATED WITH PROSTATE CANCER SCREENING AMONG HISPANIC MEN: RESULTS FROM HISPANIC COMMUNITY HEALTH STUDY/STUDY OF LATINOS (HCHS/SOL)13
RETROPERITONEAL NODAL DISTRIBUTION OF METASTATIC SEMINOMA: A CLINICAL MAPPING STUDY13
Morbidity and mortality of salvage radical prostatectomy for prostate cancer: An analysis of the National surgical quality improvement program targeted prostatectomy database13
Molecular mechanism of microRNAs, long noncoding RNAs, and circular RNAs regulating lymphatic metastasis of bladder cancer13
Understanding the role of statin use on advanced prostate cancer outcomes: Does the statin type, cumulative dose, or duration impact survival?13
EDARADD silencing suppresses the proliferation and migration of bladder cancer cells13
Nivolumab plus gemcitabine–cisplatin for previously untreated unresectable or metastatic urothelial carcinoma: an Asian subgroup analysis from the global phase 3 CheckMate 901 trial13
Exploring the tumor-promoting function and prognostic value of ESPL1 in prostate adenocarcinoma13
Featured SUO Fellow: Parth Thakker, MD12
Implications of hemoglobin, albumin, lymphocyte, platelet (HALP) score as a predictor of neoadjuvant chemotherapy response in bladder cancer patients12
Predictive value of the HAS-BLED score in the course of radical cystectomy: A pilot study12
Assessing the sex-based enrollment gap in urologic oncology clinical trials12
Clinical outcomes of deferred cytoreductive nephrectomy after initial systemic therapy in metastatic renal cell carcinoma: A multicenter retrospective study12
Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think Tank12
MRI-GUIDED TRANSURETHRAL ULTRASOUND ABLATION (TULSA) OF LOCALIZED PROSTATE CANCER: SINGLE INSTITUTION EXPERIENCE OF TREATMENT EFFICACY12
Emerging role of urinary biomarkers in bladder cancer diagnosis and prognosis11
Pathology focused review of morphologic subtypes and molecular variants of urothelial carcinoma with an emphasis on clinical/treatment relevance11
Chronic kidney disease and radical cystectomy for bladder cancer: perioperative and oncologic outcomes in 1,214 patients11
Editorial Board11
A polygenic risk score is associated with risk of bladder cancer and earlier age of diagnosis, independent of lifestyle factors11
Emergence of triplet therapy for metastatic castration-sensitive prostate cancer: An updated systematic review and network meta-analysis11
Re: Hera et al. impact of neoadjuvant therapy on prognosis in renal cell carcinoma with inferior vena cava thrombus11
The impact of bladder cuff excision on outcomes after nephroureterectomy for upper tract urothelial carcinoma: An analysis of the ROBUUST 2.0 registry11
First-line therapy for metastatic renal cell carcinoma: A propensity score-matched comparison of efficacy and safety11
Impact of the time elapsed between prostate biopsy and surgery on the accuracy of nomograms predicting lymph node invasion in patients with clinically localized prostate cancer11
Cover 2 - Masthead11
Development of a predictive model for recurrence-free survival in pTa low-grade bladder cancer10
Impact of smoking exposure on disease progression in high risk and very high-risk nonmuscle invasive bladder cancer patients undergoing BCG therapy10
HIVEC as an alternative option in non-muscle-invasive bladder cancer: Experiences from a high-volume center10
PHASE 3 MK-5684-004 STUDY OF CYP11A1 INHIBITOR OPEVESOSTAT VERSUS NEXT-GENERATION HORMONAL AGENT (NHA) SWITCH IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER 1 PRIOR NHA10
Evaluation of short term surgical outcomes of radical prostatectomy in the decade following the introduction of minimum volume standards in the Netherlands10
Retraction notice to “microRNA-107 functions as a candidate tumor suppressor gene in renal clear cell carcinoma involving multiple genes” [Urologic Oncology: Seminars and Original Investigations 33 (210
Disparities in access to high-volume centers and in hospital discharge status following radical cystectomy in Florida10
Leveraging DNA repair deficiency to personalize radiopharmaceutical therapy in prostate cancer10
LOW-GRADE AND HIGH-GRADE INTERMEDIATE-RISK NON-MUSCLE-INVASIVE BLADDER CANCER RESPOND DIFFERENTLY TO BACILLUS CALMETTE-GUÉRIN AND GEMCITABINE-DOCETAXEL10
Genitourinary toxicity in patients receiving TURP prior to hypofractionated radiotherapy for clinically localized prostate cancer: A scoping review10
Specialty differences in treatment recommendations for low-risk prostate cancer10
Commentary on: “Adjuvant vs. salvage radiotherapy in men with pathologically node-positive prostate cancer after radical prostatectomy”10
SURVIVAL PATTERNS BASED ON SITE-SPECIFIC VISCERAL METASTASIS IN METASTATIC PROSTATE CANCER PATIENTS: ARE OUTCOMES OF VISCERAL METASTASES THE SAME?10
Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer: An Analysis of Real-World Practice Patterns from the CancerLinQ Database10
Editorial Board9
BLOOD-BASED LIQUID BIOPSY IN DIAGNOSIS, SURVEILLANCE, AND PROGNOSIS OF PATIENTS WITH PRIMARY UPPER TRACT UROTHELIAL CARCINOMA9
PSMA PET/CT-DETECTED MESORECTAL LYMPH NODE METASTASES: TREATMENT OUTCOMES AND CLINICAL IMPLICATIONS9
Pattern and risk factors of local recurrence and intravesical recurrence after segmental ureterectomy for upper tract urothelial carcinoma9
Masculinity stigma and metastatic prostate cancer: A review with a focus on Latin America9
Urothelial carcinoma of the bladder with isolated lymph node metastasis: Natural history and outcomes following surgical resection9
Prostate magnetic resonance imaging utilization and its relationship with advanced prostate cancer detection9
Development of a specific supportive care needs scale for radical cystectomy patients and its reliability and validity test9
LARGE LANGUAGE MODEL FOR PROVIDING PATIENT-FOCUSED GUIDANCE FOLLOWING RADICAL PROSTATECTOMY9
CHANGES IN PROSTATE SPECIFIC ANTIGEN SCREENING FOLLOWING THE 2018 UNITED STATES PREVENTIVE SERVICES TASK FORCE GUIDELINES AND THROUGH THE COVID-19 PANDEMIC9
Table of Contents9
Pathologic and Short-Term Oncologic Outcomes of Prostate Cancer Patients Following Transvesical Robot-Assisted Radical Prostatectomy9
Opioid prescription following radical orchiectomy associated with new persistent opioid use9
Assessing the impact of lymphovascular invasion on overall survival in surgically treated renal cell carcinoma patients: A nationwide cohort analysis9
Evaluating surrogates for overall survival in the adjuvant treatment of bladder cancer with chemotherapy9
Cover 2 - Masthead9
Sequential endoluminal gemcitabine and docetaxel for the treatment of clinically non-invasive high-grade upper tract urothelial carcinoma9
2024 Star Reviewers for Urologic Oncology9
Comparative analysis of salvage partial nephrectomy versus radical nephrectomy after the failure of initial partial nephrectomy9
Clinical parameters for the prediction of occult lymph node metastasis in patients with negative PSMA-PET9
Biodynamic prediction of neoadjuvant chemotherapy response: Results from a prospective multicenter study of predictive accuracy among muscle-invasive bladder cancer patients9
Unraveling the BMI paradox in different renal cortical tumors: insights from the INMARC registry9
State of the Art: The Microbiome in Bladder Cancer9
Clinical outcomes of retreatment or discontinuation after interruption of nivolumab plus ipilimumab due to immune-related adverse events in metastatic renal cell carcinoma patients: A retrospective mu8
INCIDENCE AND PATHOLOGIC OUTCOMES OF CYSTECTOMY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN-UNRESPONSIVE NON–MUSCLE-INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU FOLLOWING TREATMENT WITH NADOFARAGENE F8
EARLY POSTOPERATIVE CANCER-SPECIFIC DEATH AMONGST PATIENTS WITH HIGH-RISK NON-METASTATIC CLEAR CELL RENAL CELL CARCINOMA: REFINING RISK STRATIFICATION TO OPTIMIZE SELECTION FOR ADJUVANT THERAPY8
2023 Star Reviewers for Urologic Oncology8
Quality of life for men with metastatic castrate-resistant prostate cancer participating in an aerobic and resistance exercise pilot intervention8
The 5-item frailty index predicts 30-day morbidity and mortality in radical nephrectomy patients: A propensity matched analysis8
Interpreting clear cell renal neoplasm pathology reports: Practical guidance for urologists8
Diagnostic performance of Cxbladder Triage Plus for the identification and stratification of patients at risk for urothelial carcinoma: The multicenter, prospective, observational DRIVE study8
THE NONCANONICAL WNT PATHWAY (FYN/STAT3) ACTIVATED BY YY1 PROMOTES THE NEUROENDOCRINE DIFFERENTIATION OF PROSTATE CANCER CELLS.8
Deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma: A systematic review and patient-level meta-analysis8
HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER WITH VARIANT HISTOLOGY OR OTHER SUBTYPES NOT A PREDICTOR FOR PROGRESSION IN BCG-TREATED PATIENTS8
INTRAVESICAL AUTOLOGOUS TIL THERAPY IN BCG-EXPOSED NMIBC: A REPORT OF EARLY SAFETY AND EFFICACY FINDINGS8
Thermal ablation for local tumor recurrence after previous partial nephrectomy: Perioperative and oncological outcomes8
Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: A comparison of patients initiated on apalutamide or enzalutamide8
Electronic nose-based urinary volatilome profiling accurately discriminates bladder cancer from healthy controls: A prospective diagnostic study8
Characteristics Contributing to Survival Differences Between Black and White Patients Following Cystectomy8
A systematic review and meta-analysis of clinicopathologic factors associated with adverse oncologic outcomes in bladder cancer patients undergoing radical cystectomy: Evidence from multivariable surv8
THE PROGNOSTIC SIGNIFICANCE OF CIRCULATING TUMOR DNA IN PATIENTS WITH POSITIVE LYMPH NODE DISEASE AFTER ROBOTIC-ASSISTED RADICAL CYSTECTOMY8
QUANTIFYING THE BENEFIT OF SALVAGE RADIATION THERAPY FOR BIOCHEMICALLY RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMY8
Investigating the pattern of prostate specific antigen screening among E-cigarette smokers within the behavioral risk factor surveillance system8
A PHASE IIB RANDOMIZED PLACEBO-CONTROLLED TRIAL TESTING A LONG-CHAIN OMEGA-3 FATTY ACID MAG-EPA DIETARY SUPPLEMENT ON PROSTATE CANCER AND GUT MICROBIOME8
Editorial Board8
THE PROGNOSTIC ROLE OF THE NEUTROPHIL-TO-LYMPHOCYTE RATIO (NLR) IN HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER PATIENTS TREATED WITH INTRAVESICAL GEMCITABINE AND DOCETAXEL8
LEVEL OF NODAL METASTASIS IN PATIENTS UNDERGOING RADICAL CYSTECTOMY AND LYMPHADENECTOMY: IS THERE A ROLE OF EXTENDED LYMPHADENECTOMY IN THE POST-S1011 ERA?8
Socioeconomic determinants of racial disparities in survival outcomes among patients with renal cell carcinoma8
Contemporary outcomes for robotic radical cystectomy and intracorporeal neobladder urinary diversion8
Impact of intraoperative intravenous heparin bolus on clinical outcomes during radical nephrectomy and IVC tumor thrombectomy in renal cell carcinoma with level I–IV IVC thrombus: A multi-institutiona8
MAPPING PATTERNS OF RECURRENCE AFTER SALVAGE LYMPH NODE DISSECTION IN PATIENTS WITH METASTATIC PROSTATE CANCER8
Actionable genomic landscapes from a real-world cohort of urothelial carcinoma patients8
Table of Contents8
Diagnostic yield of upper tract imaging performed for hematuria screening: Results from a national, privately-insured cohort8
Costs of care and oncologic outcomes associated with blue light cystoscopy in an equal access setting: Results from the BRAVO study7
Steroidogenesis in castration-resistant prostate cancer7
The relationship between BCG immunotherapy and oxidative stress parameters in patients with nonmuscle invasive bladder cancer7
Artificial intelligence in prostate cancer imaging: A mini-review of current applications and future directions7
Disparities and temporal trends in referral for bladder cancer diagnosis: A worsening epidemic7
The evolving global burden of kidney cancer: A comparative analysis of trends in China and worldwide with projections to 20417
Rates of volume reduction after selective arterial embolization for renal angiomyolipoma7
Intra-arterial chemotherapy combined with BCG immunotherapy is more effective than intra-arterial chemotherapy plus intravesical chemotherapy or standard BCG immunotherapy in preventing the recurrence7
Clinically significant prostate cancer detection rate in biopsy-naïve patients with mpMRI and microultrasound topographically discordant lesions: A single-center retrospective analysis7
THE DISPARITY OF LYMPH NODE DISSECTION IN T2+N0M0 STAGE PENILE SQUAMOUS CELL CARCINOMA PATIENTS7
Michael Droller: An appreciation, for his Festschrift 20247
Efficacy and safety of axitinib for metastatic renal cell carcinoma: Real-world data on patients with renal impairment7
Preoperative risk calculator for the probability of completing nephron sparing for kidney cancer7
“I was in a very deep, dark place... I wasn't prepared for that”: A qualitative assessment of the emotional well-being needs of patients undergoing cystectomy7
Progression-free survival with darolutamide and docetaxel vs. androgen receptor pathway inhibitors vs. docetaxel in metastatic hormone-sensitive prostate cancer: A real-world multicenter retrospective7
The role of autophagy dysregulation in low and high-grade nonmuscle invasive bladder cancer: A survival analysis and clinicopathological association7
Clinicopathological characteristics and prognosis of metastatic collecting duct carcinoma7
Molecular pathology of rare histologic variants and treatment-resistant lineages of prostate cancer7
Predictive factors for recurrence and outcomes in T1a renal cell carcinoma: Analysis of the INMARC (International Marker Consortium for Renal Cancer) database7
Epigenetics regulation of prostate cancer: Biomarker and therapeutic potential7
Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer7
STIMULATED RAMAN HISTOLOGY AND ARTIFICIAL INTELLIGENCE ALLOWS FOR PREDICTION OF PROSTATE CANCER EXTRAPROSTATIC EXTENSION AND POSITIVE SURGICAL MARGIN DURING RADICAL PROSTECTOMY7
EARLY ONCOLOGIC OUTCOME AND PSA KINETICS FOLLOWING IRREVERSIBLE ELECTROPORATION IN MEN WITH PROSTATE CANCER7
Germline testing in urothelial cancer: A narrative review of evidence, guidelines, and testing frameworks7
Intra-arterial chemotherapy plus BCG, a promising combination adjuvant treatment for high-risk NMIBC7
Prognostic significance of pathologic response to neoadjuvant chemotherapy in muscle-invasive urothelial carcinoma of the bladder with histologic subtype7
The efficacy of adjuvant mitotane therapy and radiotherapy following adrenalectomy in patients with adrenocortical carcinoma: A systematic review and meta-analysis7
Liquid biopsy testing in urological cancers: Focus on urine7
THE ASSOCIATION BETWEEN HEALTH LITERACY AND ALL-CAUSE MORTALITY IN UROLOGIC CANCER PATIENTS7
Avoiding “Needless” nephrectomy: What is the role of small renal mass biopsy in 2024?7
Comparison of adjuvant and neoadjuvant therapies for muscle invasive bladder cancer: A network meta-analysis7
Development of point-of-care tests for urinary bladder cancer – an historic review and view to future prospectives7
Therapeutic efficacy of Gemcitabine/Docetaxel maintenance in patients with non-muscle-invasive bladder cancer receiving initial Bacillus Calmette-Guérin induction7
PIVOT-006: A PHASE 3, RANDOMIZED STUDY OF ADJUVANT INTRAVESICAL CRETOSTIMOGENE GRENADENOREPVEC VERSUS SURVEILLANCE FOR THE TREATMENT OF INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER7
DEVELOPMENT AND EXTERNAL VALIDATION OF A LOCAL PELVIC RECURRENCE RISK SCORE AFTER RADICAL CYSTECTOMY: IDENTIFYING THE IDEAL CANDIDATE FOR ADJUVANT RADIATION CLINICAL TRIALS7
RISK FACTORS FOR PROGRESSION IN PATIENTS WITH POST-BCG RECURRENT NMIBC7
UnCHAARTED territory: The role of docetaxel rechallenge following chemohormonal therapy for metastatic castration-sensitive prostate cancer6
Editorial Board6
DEVELOPMENT AND TESTING OF A CUSTOM NANOSTRING RNA CODESET FOR MUSCLE-INVASIVE BLADDER CANCER UTILIZING TCGA SUBTYPING (SWOG S1011)6
Cover 2 - Masthead6
Prevalence of unnecessary kidney function exclusion criteria in urologic oncology clinical trials6
CYTOREDUCTIVE NEPHRECTOMY IS ASSOCIATED WITH IMPROVED SURVIVAL FOR SARCOMATOID METASTATIC RENAL CELL CARCINOMA PATIENTS TREATED BEFORE OR AFTER SURGERY WITH IMMUNE CHECKPOINT INHIBITORS6
Corrigendum to Deciphering the role of zingiber officinale phytochemicals for the treatment of prostate cancer: Interactions of phytochemicals with androgen receptor prostate cancer mutant H874Y ligan6
Oncogenic MicroRNAs: Key players in human prostate cancer pathogenesis, a narrative review6
Single dose perioperative intravesical instillation of gemcitabine versus mitomycin-C following resection of non-muscle invasive bladder cancer: A randomized controlled trial6
Metformin intake and risk of metabolic acidosis after radical cystectomy with urinary diversion: A comparative study using data from the TriNetX research network6
Surgical templates for inguinal lymph node dissection in cN0 penile cancer: A comparative study6
Influence of radical prostatectomy on miRNA dynamics in urine extracellular vesicles6
Sequencing impact and prognostic factors in metastatic castration-resistant prostate cancer patients treated with cabazitaxel: A systematic review and meta-analysis6
Cover 2 - Masthead6
Re: Clinical impact of detrusor muscle in en bloc resection for T1 bladder cancer. Yanagisawa T, Sato S, Hayashida Y, Okada Y, Fukuokaya W, Iwatani K, et al. J Urol Oncol. 2023;41(12):484.e7-484.e156
HPV and urological cancers: Investigating renal and prostate cancer associations6
Cause-specific mortality among patients with renal cell carcinoma in the United States from 2000 to 20186
SUBOPTIMAL REPORTING OF ADVERSE EVENTS IN RCTs SUPPORTING BLADDER CANCER CLINICAL PRACTICE GUIDELINES6
ROLE OF TUMOR MICROENVIRONMENT DERIVED NRG1 IN ANDROGEN RESISTANCE: IMPLICATIONS FOR A NOVEL PROSTATE CANCER TREATMENT STRATEGY6
Festschrift honoring Michael Droller6
GENE EXPRESSION DIFFERENCES AND PATHWAY ACTIVATION BY RACE IN ERG+ PROSTATE CANCERS: IMPLICATIONS FOR EQUITABLE CANCER CARE6
Revisiting BCG: The potential of rescue BCG therapy for BCG-unresponsive non-muscle-invasive bladder cancer6
EVALUATING CLINICAL OUTCOMES AND THE ROLE OF NEOADJUVANT CHEMOTHERAPY IN PLASMACYTOID UROTHELIAL CARCINOMA: INSIGHTS FROM A COMBINED NATIONAL AND INSTITUTIONAL SERIES6
Global trends and regional variations in PCa burden: A focus on China's rapid growth6
Clinician interest in clinical decision support for PSA-based prostate cancer screening6
Epigenetic signatures and risk determinants in bladder cancer: Implications for diagnostic and therapeutic interventions6
GRADE AND VOLUME PROGRESSION AND ITS ASSOCIATION WITH THE DECIPHER GENOMIC CLASSIFIER USING PATIENTS ENROLLED IN A PROSPECTIVE ACTIVE SURVEILLANCE PROTOCOL6
Distinct pathways of disease progression with dual checkpoint blockade versus immunotargeted therapy in metastatic renal cell carcinoma6
Prognostic impact of radiological tumor burden in patients with metastatic urothelial carcinoma treated with pembrolizumab6
Comparison of oncologic outcomes following robot-assisted radical prostatectomy in high- and very high-risk prostate cancer based on the 2025 National Comprehensive Cancer Network risk stratification6
A systematic review and meta-analysis evaluating the incidence, microbiological profile and risk factors associated with urinary tract infection after radical cystectomy6
RADIATION THERAPY AND IRREVERSIBLE ELECTROPORATION (RTIRE) FOR INTERMEDIATE RISK PROSTATE CANCER: A PHASE II ONGOING TRIAL6
Optimizing testicular cancer therapy: Survivorship perspectives on reducing late toxicities without compromising outcomes6
EARLY CLINICAL EXPERIENCE WITH SEQUENTIAL INTRAVESICAL GEMCITABINE-DOCETAXEL FOR TREATMENT-NAIVE HIGH RISK NON-MUSCLE INVASIVE BLADDER CANCER6
CONCORDANCE BETWEEN CLINICAL AND PATHOLOGIC STAGING OF T2A-B AND T3A RENAL CELL CARCINOMA: IMPLICATIONS FOR FUTURE PERIOPERATIVE CLINICAL TRIALS6
Transperineal 3T MRI-guided and transrectal MRI-ultrasound fusion prostate biopsies: Do lesion location and size impact diagnostic yield?6
DEVELOPMENT AND VALIDATION OF A NOVEL NOMOGRAM TO PREDICT LYMPH NODE INVASION IN UPPER TRACT UROTHELIAL CARCINOMA6
COMPARING ACTIVE SURVEILLANCE AND WATCHFUL WAITING AND RADICAL TREATMENT USING MACHINE LEARNING MODELS AMONG PROSTATE CANCER PATIENTS6
Cachexia index in predicting outcomes among patients receiving immune checkpoint inhibitor treatment for metastatic renal cell carcinoma6
Impact of surgical margin and extent of lymphadenectomy on oncologic outcomes in plasmacytoid urothelial carcinoma6
Contemporary morbidity and mortality of open versus robotic cystectomy for bladder cancer: An analysis of the National Surgical Quality Improvement Program (NSQIP) procedure targeted cystectomy databa6
Multigenerational VHL family characterized by pathogenic germline ELOC variant: Response to belzutifan6
CARCINOMA IN SITU AND URINARY CYTOLOGY AS AN INDICATOR OF MINIMAL RESIDUAL DISEASE IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER TREATED WITH BCG6
A comprehensive assessment of frailty status on surgical, functional and oncologic outcomes in patients treated with partial nephrectomy—A large, retrospective, single-center study6
SEQUENTIAL ENDOLUMINAL GEMCITABINE AND CABAZITAXEL WITH SYSTEMIC PEMBROLIZUMAB FOR RECURRENT NON-MUSCLE INVASIVE UROTHELIAL CARCINOMA OF THE UPPER AND LOWER URINARY TRACTS6
0.21368098258972